Showing results (1031-1040 of 1,080) with videos related to

Sort By:
Pageof 108
European Journal of Heart Failure|May 1, 2021
Heart failure with preserved ejection fraction according to the HFA-PEFF score in COVID-19 patients: clinical correlates and echocardiographic findingsSara Hadzibegovic, Alessia Lena, Timothy W Churchill, et al.
Human Mutation|May 9, 2019
Novel variants and clinical symptoms in four new ALG3-CDG patients, review of the literature, and identification of AAGRP-ALG3 as a novel ALG3 variant with alanine and glycine-rich N-terminusNastassja Himmelreich, Bianca Dimitrov, Virginia Geiger, et al.
Hemasphere|June 16, 2025
Prognostic significance of PET/CT for CAR T cell therapy in relapsed/refractory multiple myelomaPatrick Born, David Fandrei, Song Yau Wang, et al.
Journal of Neuroendocrinology|December 14, 2023
Use and perceived utility of [<sup>18</sup> F]FDG PET/CT in neuroendocrine neoplasms: A consensus report from the European Neuroendocrine Tumor Society (ENETS) Advisory Board Meeting 2022Valentina Ambrosini, Martyn Caplin, Justo P Castaño, et al.
Human Genetics|August 10, 2006
Clinical and molecular genetic features of ARC syndromePaul Gissen, Louise Tee, Colin A Johnson, et al.
Frontiers in Immunology|August 8, 2025
CREB regulates Foxp3<sup>+</sup>ST-2<sup>+</sup> T<sub>REGS</sub> with enhanced IL-10 productionSudheendra Hebbar Subramanyam, Judit Turyne Hriczko, Saskia Schulz, et al.
American Journal of Preventive Medicine|December 28, 2020
Determinants of Human Papillomavirus Vaccine Uptake by Adult Women Attending Cervical Cancer Screening in 9 European CountriesClaudia Robles, Laia Bruni, Amelia Acera, et al.
Journal of Neuroendocrinology|December 9, 2024
Challenges in developing response evaluation criteria for peptide receptor radionuclide therapy: A consensus report from the European Neuroendocrine Tumor Society Advisory Board Meeting 2022 and the ENETS Theranostics Task ForceVikas Prasad, Anna Koumarianou, Timm Denecke, et al.
Hemasphere|April 6, 2026
Body composition predicts poor outcomes and reveals immunometabolic dysfunction via single-cell profiling in anti-BCMA CAR T-treated myelomaThomas C Wiemers, Michael Rade, Nora Grieb, et al.
Leukemia|November 25, 2018
JAK2V617F but not CALR mutations confer increased molecular responses to interferon-α via JAK1/STAT1 activationJulia Czech, Sabrina Cordua, Barbora Weinbergerova, et al.
Pageof 108